News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer.
To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP for two bispecific antibodies that treat multiple myeloma and lymphoma.
The top stories:
Partnership could enhance antibody discovery for cancer research
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries.
CHMP recommendation for bispecific antibody talquetamab
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab).
Bispecific antibody a “promising treatment option” for DLBCL
The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly).
New class of antibody cancer drug shows promise
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working.
New eBook: Breakthroughs accelerating therapeutic antibodies
The latest eBook by DDW is out now. This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector.
